Tenofovir for the Prevention of HCC in Patients With Cirrhosis
- PMID: 31850932
- DOI: 10.14309/ajg.0000000000000477
Tenofovir for the Prevention of HCC in Patients With Cirrhosis
Comment in
-
Inhibitory Effect of Nucleos(t)ide Analogs on Telomerase Activity and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.Am J Gastroenterol. 2020 Feb;115(2):302-303. doi: 10.14309/ajg.0000000000000507. Am J Gastroenterol. 2020. PMID: 31913195 No abstract available.
Comment on
-
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.Am J Gastroenterol. 2020 Feb;115(2):271-280. doi: 10.14309/ajg.0000000000000428. Am J Gastroenterol. 2020. PMID: 31634265
References
-
- Hsu YC, Wong GLH, Chen CH, et al. Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B. Am J Gastroenterol 2019;115:271–80.
-
- Nault JC, Ningarhari M, Rebouissou S, et al. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol 2019;16:544–58.
-
- Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: A potential factor contributing to HIV-associated accelerated aging. J Infect Dis 2013;207:1157–65.
-
- Kitada T, Seki S, Kawakita N, et al. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun 1995;211:33–9.
-
- Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 2019;179:561–77.e22.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical